Edition:
United Kingdom

Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

32.78USD
23 Apr 2018
Change (% chg)

$-0.03 (-0.09%)
Prev Close
$32.81
Open
$32.79
Day's High
$32.99
Day's Low
$32.65
Volume
45,651
Avg. Vol
225,185
52-wk High
$36.33
52-wk Low
$29.25

Chart for

About

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $7,880.51
Shares Outstanding(Mil.): 230.83
Dividend: 1.08
Yield (%): --

Financials

  QGEN.N Industry Sector
P/E (TTM): 104.06 84.02 32.74
EPS (TTM): 0.33 -- --
ROI: 1.87 1.58 14.38
ROE: 2.97 2.41 16.07

BRIEF-Qiagen NV Announces European Launch Of Qiastat-Dx

* QIAGEN ANNOUNCES EUROPEAN LAUNCH OF QIASTAT-DX®, A NEXT GENERATION PLATFORM FOR SYNDROMIC INSIGHTS Source text for Eikon: Further company coverage:

19 Apr 2018

BRIEF-Pangaea Oncology Signs Strategic Deal In Oncological Diagnosis With Qiagen

* SAYS SIGNS STRATEGIC AGREEMENT IN ONCOLOGICAL DIAGNOSIS WITH GERMAN DIAGNOSTIC MULTINATIONAL QIAGEN

09 Apr 2018

BRIEF-‍Qiagen's QuantiFERON-TB Gold Plus Gains Approval In Japan​

* ‍QIAGEN'S QUANTIFERON-TB GOLD PLUS GAINS APPROVAL IN JAPAN​

08 Feb 2018

BRIEF-Qiagen to conduct an up to $200 mln share repurchase program

* DGAP-ADHOC: QIAGEN N.V.: QIAGEN TO CONDUCT AN UP TO US$200 MILLION SHARE REPURCHASE PROGRAM

31 Jan 2018

BRIEF-Qiagen Q4 Loss Per Share $0.18 Including Items

* QIAGEN REPORTS RESULTS FOR FOURTH QUARTER AND FULL-YEAR 2017, ANNOUNCES STAT-DX ACQUISITION AND NEW $200 MILLION SHARE REPURCHASE

31 Jan 2018

BRIEF-Qiagen Signs Agreement To Acquire Stat-Dx

* QIAGEN ENTERS INTO AGREEMENT TO ACQUIRE STAT-DX, PLANS TO LAUNCH A NEXT-GENERATION, FULLY INTEGRATED MULTIPLEX PLATFORM FOR SYNDROMIC DISEASE TESTING

31 Jan 2018

BRIEF-Qiagen NV Receives FDA Clearance For Ipsogen Jak2 RGQ PCR Kit

* QIAGEN NV SAYS RECEIVED CLEARANCE FOR ITS IPSOGEN JAK2 RGQ PCR KIT FROM U.S. FDA FOR ADDITIONAL USE IN DIAGNOSIS OF ALL MYELOPROLIFERATIVE NEOPLASMS Source text for Eikon: Further company coverage:

23 Jan 2018

Earnings vs. Estimates